| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
130,390,000 |
| Market
Cap: |
41.98(B) |
| Last
Volume: |
632,571 |
Avg
Vol: |
750,867 |
| 52
Week Range: |
$165.7 - $312.32 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 529 |
| Guru Rank Value : 3.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
36 |
36 |
| Total Buy Value |
$0 |
$0 |
$10,363 |
$10,363 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
62,223 |
167,227 |
284,859 |
441,513 |
| Total Sell Value |
$18,668,384 |
$47,737,729 |
$78,332,071 |
$106,431,317 |
| Total People Sold |
3 |
9 |
11 |
13 |
| Total Sell Transactions |
4 |
27 |
45 |
65 |
| End Date |
2025-03-27 |
2024-12-24 |
2024-06-25 |
2023-06-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-06-02 |
4 |
AS |
$306.00 |
$5,904,882 |
D/D |
(19,297) |
48,948 |
|
1% |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-06-02 |
4 |
OE |
$118.05 |
$2,291,057 |
D/D |
19,297 |
68,245 |
|
- |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-05-30 |
4 |
AS |
$304.00 |
$9,630,902 |
D/D |
(31,640) |
48,948 |
|
2% |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-05-30 |
4 |
OE |
$118.05 |
$3,748,149 |
D/D |
31,640 |
80,588 |
|
- |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-05-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
8,376 |
48,948 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2025-05-15 |
4 |
AS |
$267.14 |
$3,124,217 |
D/D |
(11,250) |
16,804 |
|
9% |
|
| Bonney Michael W |
Director |
– • – |
2025-05-15 |
4 |
OE |
$131.21 |
$1,476,113 |
D/D |
11,250 |
28,054 |
|
- |
|
| Bertozzi Carolyn R |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
775 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
911 |
|
- |
|
| Hamburg Margaret A |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
911 |
|
- |
|
| Reitan Colleen F |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
775 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
911 |
|
- |
|
| Schulman Amy W |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
11,961 |
|
- |
|
| Brandicourt Olivier |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
775 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
16,804 |
|
- |
|
| Kellogg Peter N |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
775 |
|
- |
|
| Sigal Charles Elliott |
Director |
– • – |
2025-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
775 |
|
- |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-05-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
41,311 |
57,324 |
|
- |
|
| Reitan Colleen F |
Director |
– • – |
2025-04-16 |
4 |
S |
$232.86 |
$8,383 |
D/D |
(36) |
0 |
|
-41% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-24 |
4 |
AS |
$300.00 |
$1,633,500 |
D/D |
(5,445) |
20,221 |
|
7% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-24 |
4 |
OE |
$42.22 |
$229,888 |
D/D |
5,445 |
25,666 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2025-03-24 |
4 |
AS |
$299.00 |
$2,224,560 |
D/D |
(7,440) |
136 |
|
7% |
|
| Pyott David E I |
Director |
– • – |
2025-03-24 |
4 |
OE |
$88.95 |
$661,788 |
D/D |
7,440 |
7,576 |
|
- |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-21 |
4 |
AS |
$285.00 |
$1,231,485 |
D/D |
(4,321) |
20,221 |
|
9% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-04 |
4 |
AS |
$239.25 |
$194,766 |
D/D |
(808) |
24,542 |
|
27% |
|
493 Records found
|
|
Page 1 of 20 |
|
|
3.06 (0.94%) 
